Amini, Leila http://orcid.org/0000-0003-4855-5905
Silbert, Sara K.
Maude, Shannon L.
Nastoupil, Loretta J. http://orcid.org/0000-0001-6071-8610
Ramos, Carlos A. http://orcid.org/0000-0002-4004-7837
Brentjens, Renier J. http://orcid.org/0000-0002-3364-5388
Sauter, Craig S.
Shah, Nirali N. http://orcid.org/0000-0002-8474-9080
Abou-el-Enein, Mohamed http://orcid.org/0000-0003-2903-9040
Article History
Accepted: 10 February 2022
First Online: 22 March 2022
Competing interests
: S.L.M. has acted as a consultant and/or adviser of and has received research funding from Novartis and Wugen. L.J.N. has received honoraria from ADC Therapeutics, Bayer, BMS/Celgene, Epizyme, Genentech, Gilead/Kite, Janssen, Morphosys, Novartis, Pfizer, TG Therapeutics; and has received research funding from BMS/Celgene, Caribou Biosciences, Epizyme, Genentech, Gilead/Kite, IGM Biosciences, Janssen, Novartis, Pfizer, TG Therapeutics. C.A.R. has acted as an adviser of Novartis and has received research funding from Athenex and Tessa Therapeutics. R.J.B. has licensed intellectual property to and collects royalties from BMS, Caribou and Sanofi; has received research funding from BMS; has acted as a consultant of Atara Biotherapeutics, BMS and Gracell Biotechnologies. C.S.S. has acted as a consultant of Celgene/BMS, Gamida Cell, Genmab, GSK, Juno Therapeutics, Karyopharm Therapeutics, Kite/a Gilead Company, Novartis, Precision Biosciences, Sanofi-Genzyme, and Spectrum Pharmaceuticals and has received research funding from Celgene/BMS, Bristol-Myers Squibb, Juno Therapeutics, Precision Biosciences and Sanofi-Genzyme. L. A., S.K.S., N.N.S. and M.A. declare no competing interests.